logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Baocheng (02378.HK) spent 2.544 million pounds on May 30 to repurchase 300,000 shares.

date
04/06/2025
Wisdom Finance app news, BOCOM International (02378.HK) announced that on May 30, 2025, it will spend 2.544 million pounds to repurchase 300,000 shares.
Latest
1 m ago
Kangfang confirms that the medical representative forged materials to obtain cancer drugs through deception.
2 m ago
Longhua New Materials: Company's terminal aminopolyether technical transformation project has obtained approval.
4 m ago
Wei Long's delicious increased capital to $81.06 million, an increase of approximately 23%.
5 m ago
Hansun Pharmaceuticals: Alectinib Hydrochloride Tablets Approved by the UK Medicines and Healthcare Products Regulatory Agency for Market Authorization.
5 m ago
Hansun Pharmaceuticals: Amebithin Hydrochloride Tablets Approved for Marketing by the UK Medicines and Healthcare Products Regulatory Agency.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.